UK small-cap RNS · 2 Jul 2026
Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.
Key = all announcements except routine filings (voting rights, buybacks, holdings, director forms), plus the ones that are part of a situation. Not investment advice.
| Time | Company | Mcap ↕ | Type | Announcement | |
|---|---|---|---|---|---|
| 14:00 | Triad Group TRD | £67m | Insider conviction | Director/PDMR Shareholding | |
| 09:15 | Team TEAM | £18m | Insider conviction | Director/PDMR Shareholding | |
| 07:24 | Capricorn Energy CNE | £291m | Takeover target | Recommended cash acquisition of Capricorn by Genel
(a company indirectly owned by Genel Energy plc ("Genel")) |
|
| 07:01 | PureTech Health PRTC | £268m | Disposal of a part (break-up) | PRTC Launches Celea w/ $180M & Top Tier Syndicate
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF) |
|
| 07:00 | ECO Animal Health Group EAH | £64m | Project milestones | EU launch of ECOVAXXIN® MS
ECO Animal Health Group plc (AIM: EAH), a leading global animal health company marketing and developing branded veterinary products to improve livestock productivity and welfare, announces the commercial launch of ECOVAXXIN® MS, its poultry vaccine against … |
|
| 07:00 | PureTech Health PRTC | £268m | Disposal of a part (break-up) | $180M & Asset Transfer
PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF) |
|
| 07:00 | Baltic Classifieds Group BCG | £786m | Capital return | Final Results
Baltic Classifieds Group PLC ("BCG", the "Company" and the "Group"), the leading online classifieds group in the Baltics, announces full year results for the year ended 30 April 2026 |
|
| 07:00 | Trifast TRI | £108m | Turnaround plan with targets | Final Results
Audited results for the year ended 31 March 2026 |
|
| 07:00 | Redcentric RCN | £86m | Capital return | Update on Capital Reduction
Redcentric plc (LSE: RCN), a leading UK IT managed services provider ('MSP'), announces that following the Final Court Hearing held on 30 June 2026 in connection with the proposed Capital Reduction, as described in the circular to Shareholders published on 24 … |
|
| 07:00 | Concurrent Technologies CNC | £250m | Transformational contract / build-out | $9.4m US Defence Production Order
Design win milestone secured as US defence programme enters production phase |
|
| 07:00 | Currys CURY | £1,473m | Capital return | Building an ever-stronger Currys
Audited Financial Results for the Year Ended 2 May 2026 |
|
| 07:00 | Zephyr Energy ZPHR | £65m | Sale process / strategic review | Acquisition of further Paradox Basin acreage
Zephyr Energy plc (AIM: ZPHR) (OTCQB: ZPHRF) is pleased to announce a further increase in its operated land position in the Paradox Basin, Utah, U.S. |